Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Movantik vs PEG 3350 Preference in OIC
NCT03060512Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2017
- Primary completion
- Aug 2017
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 4 trial of naloxegol in opioid-induced constipation (OIC), sponsored by AstraZeneca. Started Mar 2017; status: completed.
02
Drugs
naloxegol
03
Conditions
opioid-induced constipation (OIC)
Beyond the preview
Go deeper on NCT03060512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03060512.